Thermo Fisher Opens $18M Immunodiagnostics Distribution Centre In Uppsala To Strengthen Global Supply Chain

Thermo Fisher Scientific has inaugurated a new 8,000-square-meter distribution and labelling centre in Uppsala to strengthen its global immunodiagnostics supply chain. The facility will support the distribution of in vitro diagnostic (IVD) tests used in identifying allergic and autoimmune diseases, helping the company meet rising demand from healthcare systems worldwide.

Allergic and autoimmune conditions impact nearly two billion people globally, highlighting the growing need for accurate and accessible diagnostic tools. From its established immunodiagnostics hub in Uppsala, Thermo Fisher manufactures diagnostic tests that help clinicians diagnose and manage these conditions for millions of patients each year.

“The investment in the distribution and labelling centre is part of our long-term growth strategy in Sweden and reflects our commitment to meeting future customer demand globally,” said Martin Kjellsson, site leader for Thermo Fisher’s immunodiagnostics business in Uppsala. “By strengthening our logistics capabilities, we are better positioned to scale for future volume while continuing to deliver high-quality products and service to our customers.”

The new center represents an investment of approximately $18 million (around 160 million SEK) and adds advanced logistics capabilities to Thermo Fisher’s existing research, development, and manufacturing operations in the region. The expansion is designed to enhance operational efficiency, improve distribution capacity, and ensure reliable global delivery of diagnostic products.

Equipped with automated storage, scanning, and labeling systems, the facility improves accuracy, traceability, and processing speed. Built in accordance with Thermo Fisher’s global facility standards, the site also incorporates energy-efficient design features to support sustainable operations.

“Our immunodiagnostics business is focused on enabling patients around the world to receive a timely and accurate diagnosis for allergic and autoimmune diseases,” said Santhosh Nair, president of Thermo Fisher’s immunodiagnostics business. “This investment in Uppsala reflects our continued commitment to innovation, operational excellence and to our Mission to enable our customers to make the world healthier, cleaner and safer.”

Thermo Fisher’s immunodiagnostics business in Uppsala traces its origins to research conducted at Uppsala University, where scientists discovered immunoglobulin E (IgE) more than 50 years ago, a milestone that transformed modern allergy diagnostics. Today, the company’s diagnostics portfolio includes instruments marketed under the Phadia platform, as well as ImmunoCAP and EliA tests.